

NCT02760251 comparison:

Summary:
CHIA has 25 criteria while your personal folder has 25 criteria
Total found criteria: 25/25
Total not Found: 0/25
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Informed consent as documented by signature (see   │ Informed consent as documented by signature (see   │
│ informed consent form)                             │ informed consent form)                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Primary ITP according to the definition of         │ Primary ITP according to the definition of         │
│ Rodeghiero et al. (52) and a platelet count of     │ Rodeghiero et al. (52) and a platelet count of     │
│ <30x109/l                                          │ \<30x109/l                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age range: 18-45 years                             │ Age range: 18-45 years                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previously treated patients, with failure or       │ Previously treated patients, with failure or       │
│ intolerance to first-line therapy, or relapse      │ intolerance to first-line therapy, or relapse      │
│ after first-line therapy, i.e. corticosteroids,    │ after first-line therapy, i.e. corticosteroids,    │
│ intravenous immunoglobulin (IVIG), or anti-D       │ intravenous immunoglobulin (IVIG), or anti-D       │
│ immunoglobulins                                    │ immunoglobulins                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adults older than 45 and children younger than 18  │ Adults older than 45 and children younger than 18  │
│ years                                              │ years                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count higher than 30x109/l at time of     │ Platelet count higher than 30x109/l at time of     │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Suspicion of secondary ITP                         │ Suspicion of secondary ITP                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive family history for ITP                    │ Positive family history for ITP                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence or history of autoimmune disease as       │ Presence or history of autoimmune disease as       │
│ judged by the investigator                         │ judged by the investigator                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hepatosplenomegaly                                 │ Hepatosplenomegaly                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence or history of relevant hepatic disease as │ Presence or history of relevant hepatic disease as │
│ judged by the investigator                         │ judged by the investigator                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence or history of thromboembolic disease as   │ Presence or history of thromboembolic disease as   │
│ judged by the investigator                         │ judged by the investigator                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with splenectomy                          │ Patients with splenectomy                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are pregnant or breast feeding           │ Women who are pregnant or breast feeding           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Intention to become pregnant during the course of  │ Intention to become pregnant during the course of  │
│ the study                                          │ the study                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Lack of safe double contraception (see 7.1)        │ Lack of safe double contraception (see 7.1)        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any vaccination 2 weeks prior start of the study   │ Any vaccination 2 weeks prior start of the study   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Drugs with a known impact on the immune system or  │ Drugs with a known impact on the immune system or  │
│ on platelet function must be recorded and an       │ on platelet function must be recorded and an       │
│ exclusion of the study should be discussed with    │ exclusion of the study should be discussed with    │
│ the study center                                   │ the study center                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known or suspected non-compliance, drug or alcohol │ Known or suspected non-compliance, drug or alcohol │
│ abuse                                              │ abuse                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to follow the procedures of the study,   │ Inability to follow the procedures of the study,   │
│ e.g. due to language problems, psychological       │ e.g. due to language problems, psychological       │
│ disorders, dementia of the study subject           │ disorders, dementia of the study subject           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in another study with                │ Participation in another study with                │
│ investigational drug within the 30 days preceding  │ investigational drug within the 30 days preceding  │
│ and during the present study                       │ and during the present study                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous enrolment into the current study          │ Previous enrolment into the current study          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous treatment with romiplostim or eltrombopag │ Previous treatment with romiplostim or eltrombopag │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hypersensitivity to the active substance or to any │ Hypersensitivity to the active substance or to any │
│ of the excipients or to E. coli derived proteins   │ of the excipients or to E. coli derived proteins   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Enrolment of the investigator, his/her family      │ Enrolment of the investigator, his/her family      │
│ members, employees and other dependent persons     │ members, employees and other dependent persons     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
├───────────────────────────────────┤
│ Must have maximum age of 45 Years │
╘═══════════════════════════════════╛